226 related articles for article (PubMed ID: 28004478)
21. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
[TBL] [Abstract][Full Text] [Related]
22. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.
Xu Y; Lin H; Meng N; Lu W; Li G; Han Y; Dai X; Xia Y; Song X; Yang S; Wei Y; Yu L; Zhao Y
Br J Pharmacol; 2013 Aug; 169(8):1766-80. PubMed ID: 23594209
[TBL] [Abstract][Full Text] [Related]
23. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
24. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
25. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
26. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
[TBL] [Abstract][Full Text] [Related]
27. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
29. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
30. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
31. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.
Xie Q; Chen H; Ai J; Gao YL; Geng MY; Ding J; Chen Y
Acta Pharmacol Sin; 2017 Nov; 38(11):1533-1542. PubMed ID: 28795691
[TBL] [Abstract][Full Text] [Related]
34. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
35. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
[TBL] [Abstract][Full Text] [Related]
36. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
37. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.
Burkholder TP; Clayton JR; Rempala ME; Henry JR; Knobeloch JM; Mendel D; McLean JA; Hao Y; Barda DA; Considine EL; Uhlik MT; Chen Y; Ma L; Bloem LJ; Akunda JK; McCann DJ; Sanchez-Felix M; Clawson DK; Lahn MM; Starling JJ
Invest New Drugs; 2012 Jun; 30(3):936-49. PubMed ID: 21360050
[TBL] [Abstract][Full Text] [Related]
38. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
39. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
40. A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis.
Awazu Y; Mizutani A; Nagase Y; Iwata H; Oguro Y; Miki H; Imamura S; Hori A
Cancer Sci; 2012 May; 103(5):939-44. PubMed ID: 22320850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]